Lecture

Drug Development and Regulations: Europe

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Description

This lecture covers the drug development process in Europe, from discovery to marketing authorization. It explains the phases of clinical trials, the European regulatory framework, the new Clinical Trials Regulation, and the Clinical Trials Information System. The transition from the Clinical Trial Directive to the Clinical Trials Regulation is detailed, along with the life cycle of a clinical trial application. The importance of transparency in clinical trials, the Marketing Authorization Application dossier, and the different Marketing Authorization Procedures and types in Europe are also discussed.

Official source

Related concepts (31)

Clinical trial

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought.

Phases of clinical research

The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for drug safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective. Clinical research is conducted on drug candidates, vaccine candidates, new medical devices, and new diagnostic assays.

Drug development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.

Orphan drug

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation (if there is any) of the country.

Clinical research

Clinical research is a branch of healthcare science that determines the safety and effectiveness (efficacy) of medications, devices, diagnostic products and treatment regimens intended for human use. These may be used for prevention, treatment, diagnosis or for relieving symptoms of a disease. Clinical research is different from clinical practice. In clinical practice established treatments are used, while in clinical research evidence is collected to establish a treatment.

Related lectures (20)

Peptide Therapeutics

Explores the development and advantages of peptide therapeutics, including conversion into peptidomimetics and solid phase peptide synthesis.

Drug Development and Ethical Principles

Explores the historical aspects of drug development, regulatory agencies, and ethical principles in pharmacology, emphasizing the importance of informed consent and human subject protection.

Preclinical Animal Models: Selection & Rationale

Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.

Kidney-on-a-Chip Technologies

Covers the state-of-the-art kidney-on-chip technologies aiming to facilitate pharmaceutical research and eliminate animal testing.

Pharmacokinetic & Pharmacodynamic Evaluations